📊 Most US pediatric oncology centers reported using #Blinatumomab as standard therapy for standard-risk and high-risk #BCellAcuteLymphoblasticLeukemia, but outpatient delivery was often limited by lack of home care support. ja.ma/4xb4uGM

Among children with relapsed or refractory #BCellAcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. ja.ma/4hc7VYK